What metrics would you use to evaluate Moderna's mRNA-1345 RSV vaccine candidate?

Introduction

Evaluating the success of Moderna's mRNA-1345 RSV vaccine candidate requires a comprehensive approach to product metrics. This innovative vaccine represents a significant advancement in respiratory syncytial virus (RSV) prevention, particularly for older adults and high-risk populations. To assess its performance effectively, we'll employ a structured framework that encompasses core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Moderna's mRNA-1345 is a vaccine candidate targeting RSV, a common respiratory virus that can cause severe illness in older adults and young children. As an mRNA-based vaccine, it leverages similar technology to Moderna's successful COVID-19 vaccine.

Key stakeholders include:

• Patients: Seeking protection against RSV
• Healthcare providers: Administering the vaccine and managing patient care
• Regulatory bodies (e.g., FDA): Ensuring safety and efficacy
• Payers (insurance companies, governments): Assessing cost-effectiveness
• Moderna shareholders: Expecting return on investment

User flow:

1. Patient education and awareness
2. Vaccine administration (likely single dose)
3. Post-vaccination monitoring for efficacy and side effects

This vaccine fits into Moderna's broader strategy of expanding its mRNA platform beyond COVID-19. It represents a significant opportunity to address an unmet medical need, as there are currently no approved RSV vaccines for older adults.

Competitors include GSK and Pfizer, who are also developing RSV vaccines, though using different technological approaches.

Product Lifecycle Stage: Late-stage clinical development (Phase 3 trials completed), moving towards regulatory submission and potential market entry.